Genetics, Screening and Prevention

Possible warning signs include a new or enlarging lump, unexplained bleeding, persistent change in bowel or bladder habits, a cough or hoarseness that does not settle, difficulty swallowing, unexplained weight loss, a non-healing ulcer, persistent pain or marked fatigue. These symptoms are more commonly caused by non-cancerous conditions, but persistence or progression deserves assessment. There is no single symptom pattern for all cancers, and some early cancers cause no symptoms.

A new lump that persists, enlarges, feels hard or fixed, or is associated with skin change, nipple change, pain, fever or weight loss should be assessed. Lumps in the breast, neck, armpit, groin, testis or soft tissues deserve particular attention. Do not repeatedly press or massage it while waiting. Clinical examination, ultrasound or other imaging, and sometimes biopsy may be needed.

No. Weight loss can result from thyroid disease, diabetes, infection, digestive disorders, depression, medication or reduced food intake, among many causes. However, unintentional loss of about 5% or more of body weight over 6-12 months, especially with persistent symptoms, should be evaluated. Seek earlier review if weight loss is rapid or accompanied by difficulty swallowing, bleeding, a lump, fever or severe weakness.

Fever, fatigue and sweating are common and usually not caused by cancer. Medical evaluation is appropriate when they persist without a clear explanation, recur, disrupt sleep, or occur with weight loss, enlarged lymph nodes, pallor, bruising or recurrent infections. A clinician may begin with examination and basic blood tests, then select further tests based on findings. Patients already receiving cancer therapy should follow their oncology team's lower threshold for urgent review.

A cough lasting more than three weeks, worsening breathlessness, repeated chest infections, chest pain, hoarseness or any blood in sputum warrants medical assessment. Smoking history increases concern but lung cancer can also occur in non-smokers. Coughing up a large amount of blood, severe breathlessness or chest pain is an emergency. Chest imaging and other tests should be selected after clinical evaluation.

Visible blood in stool or urine should not be ignored, even if it occurs only once. Common benign causes include piles, infection and stones, but cancer and other serious conditions must sometimes be excluded. Black tarry stools, heavy bleeding, dizziness, inability to pass urine or clots with pain require urgent care. The assessment may involve examination, blood and urine tests, endoscopy or imaging.

Yes. Some cancers are detected through screening or tests performed for another reason before symptoms develop. This is why evidence-based screening is important for eligible people. However, indiscriminate scans or tumour-marker panels in healthy people can lead to false alarms and unnecessary procedures. Screening should be matched to age, sex, risk factors and family history.

No. Many people with early or localised cancer have normal routine blood counts, liver tests and kidney tests. Blood tests can identify clues, assess organ function and help plan treatment, but they rarely exclude cancer on their own. Persistent or concerning symptoms should be evaluated even when basic tests are normal. The next investigation depends on the symptom and examination.

Screening means testing people who do not have symptoms to find certain cancers or precancerous changes early. Effective programmes exist for selected cancers, including breast, cervical and colorectal cancer, and lung cancer in appropriately defined high-risk smokers. Screening is not the same as investigating a symptom. A person with symptoms needs diagnostic evaluation even if a recent screening test was normal.

Breast screening recommendations vary by country and individual risk. For average-risk women, mammography is generally offered from midlife at defined intervals; women with strong family history, prior chest radiation or a pathogenic genetic variant may need earlier and additional MRI-based surveillance. Breast awareness remains important between tests. A new lump or nipple change requires diagnostic assessment rather than waiting for the next screening date.

A rigid monthly self-examination routine has not been shown to replace mammographic screening or clinical evaluation. However, breast awareness is useful: know the usual appearance and feel of your breasts and report a new lump, skin dimpling, nipple inversion, bloody discharge or persistent focal change. Most breast changes are not cancer, but they should not be self-diagnosed. Screening schedules should be based on age and risk.

People with a cervix should follow an age-appropriate cervical screening programme using HPV testing, cytology (Pap smear) or both, depending on local guidance. Vaccination against HPV greatly reduces risk but does not remove the need for recommended screening. Screening may differ after hysterectomy, previous high-grade cervical changes, immune suppression or HIV. Abnormal bleeding or discharge requires assessment regardless of screening history.

HPV vaccination can prevent most infections with high-risk HPV types responsible for cervical cancer and several other anogenital and throat cancers. It works best before exposure to HPV, but some older adolescents and adults may also benefit after discussion with a clinician. The vaccine does not treat an existing cancer or HPV infection. Vaccinated people should still follow recommended cervical screening.

Average-risk adults should begin screening at the age recommended by national guidance, often around 45-50 years, using stool-based tests, colonoscopy or another approved strategy. Earlier assessment may be needed with a strong family history, hereditary syndrome, inflammatory bowel disease or previous polyps. Blood in stool, iron-deficiency anaemia or persistent bowel change requires diagnostic evaluation, not a screening test alone.

Annual low-dose CT screening may benefit people within a defined age range who have a substantial cigarette-smoking history and currently smoke or stopped relatively recently. It is not a routine chest X-ray and is not recommended for everyone. Eligibility and local availability should be discussed with a clinician, along with help to stop smoking. Anyone with symptoms needs diagnostic assessment rather than screening.

No blood test is currently established as a reliable general screening test for every cancer. Multi-cancer blood tests are being studied, but a positive result is not a diagnosis and a negative result cannot rule out all cancers. Such tests may lead to additional imaging and biopsies. Evidence-based organ-specific screening and prompt assessment of symptoms remain the standard approach.

Whole-body PET-CT is not recommended as a routine cancer-screening test for healthy people at average risk. It exposes the person to radiation, may miss some cancers and frequently detects benign abnormalities that lead to anxiety and invasive tests. PET-CT is valuable for selected patients after a cancer diagnosis or when a specialist has a specific clinical question. Screening should use tests proven to improve outcomes.

Usually not. Markers such as CEA, CA 19-9, CA 15-3 and CA-125 can be raised in benign conditions and may remain normal despite cancer. They are most useful in defined clinical contexts, such as assisting diagnosis, treatment selection or monitoring a known cancer. Ordering a broad marker panel in a healthy person can create false reassurance or unnecessary alarm. Exceptions, such as PSA or AFP in selected risk groups, require individual discussion.

It can. The type of cancer, relatives affected, their ages at diagnosis and whether cancers occurred across generations all matter. Some people need earlier, more frequent or different screening, and a smaller group should receive genetic counselling. Bring a written family history covering both sides of the family. Do not assume that a negative commercial genetic test automatically returns risk to average.

Sometimes, but most cancers are not caused by a single inherited variant. Families may share age, environment or behaviours, and common cancers can occur in several relatives by chance. Features suggesting hereditary risk include young diagnoses, rare cancers, multiple primary cancers in one person, bilateral disease and a characteristic combination across generations. A three-generation history from both sides of the family helps determine whether formal risk assessment is appropriate.

Counselling is useful when the personal or family history suggests an inherited syndrome, when tumour testing points to a possible germline variant, or when a result could change treatment or relatives’ prevention. Examples include epithelial ovarian cancer, male breast cancer, pancreatic cancer, metastatic or high-risk prostate cancer in selected settings, young colorectal or endometrial cancer, multiple polyps, or several related early cancers. Eligibility varies, so a genetics professional should assess the complete history.

Germline testing looks for inherited variants present from birth in nearly every cell, usually using blood or saliva. It differs from tests that examine only the tumour. Testing may focus on one known familial variant or use a panel of relevant genes. Results can affect treatment, screening, risk-reducing options and relatives. Because a result can have medical and family implications, informed consent and appropriate pre-test and post-test counselling are important.

Tumour testing looks for acquired changes in cancer cells that may classify the cancer or predict treatment response. Germline testing asks whether a variant is inherited and present throughout the body. A tumour result can suggest---but does not always prove---germline risk, while a tumour-only test can miss some inherited variants. Confirmation usually requires a separate non-tumour sample and genetics review. Patients should ask which kind of test was performed and what the report can and cannot conclude.

A pathogenic germline BRCA1 or BRCA2 variant increases the risk of certain cancers, including breast and ovarian cancer and, depending on the gene, prostate and pancreatic cancer. It can also influence treatment in some patients who already have cancer. Risk is not identical for every carrier and depends on gene, sex, age and family history. A negative result is most informative when a known family variant has been tested.

No. Most cancer-predisposition genes have incomplete penetrance, meaning not every carrier develops cancer. A positive result estimates increased risk; it does not predict exactly if, when or which cancer will occur. The practical value is the opportunity to use tailored surveillance, medication or risk-reducing surgery where evidence supports it. Decisions should be individualised and should consider age, health, reproductive plans, values and the strength of evidence for that gene.

A variant of uncertain significance, or VUS, is a DNA change for which evidence is insufficient to classify it as harmful or benign. It should not be treated like a positive result and generally should not drive preventive surgery or predictive testing in relatives. Management should be based on personal and family history. Laboratories may reclassify variants as evidence grows, so patients should keep contact details updated and review the result periodically through the testing service.

Testing healthy relatives is most informative after a pathogenic familial variant has been identified. Adult siblings and other at-risk relatives can then choose targeted testing with counselling. Children are usually tested only when the result would change medical care during childhood; testing for adult-onset risks is commonly deferred until they can participate in the decision. The inheritance pattern determines which relatives may be at risk, and both maternal and paternal histories matter.

There is no single age for every syndrome. Testing should occur early enough to guide the first recommended surveillance or preventive decision, while preserving informed choice. For adult-onset syndromes, this is often in adulthood and before the earliest relevant screening age. Childhood testing is appropriate only for genes with actionable childhood risks. A genetics professional can time testing using the specific gene, family ages at diagnosis and the relative’s readiness.

Yes. Germline or tumour variants can support use of targeted therapy, immunotherapy or particular chemotherapy in selected cancers. They may also influence surgical decisions, surveillance for second cancers and donor selection for transplant. A genetic finding does not guarantee response to a matching drug, and the same gene can have different treatment implications in different cancers. Results should be interpreted with stage, prior therapy, approvals and clinical evidence.

Surveillance should be based on the specific pathogenic variant and the relative’s own sex, age, organs, health and family history. It may start earlier, occur more often or use a different test than population screening. Some organs have no reliable screening, so risk-reducing surgery may be discussed for certain syndromes. Relatives should receive a written plan from a genetics or high-risk clinic rather than using another family member’s cancer follow-up schedule.

Yes, especially for multi-gene panels or testing an unaffected person. Pre-test counselling clarifies possible results, limitations, privacy, family implications, costs and whether testing the affected relative first would be more informative. Post-test counselling explains what a positive, negative or uncertain result means and creates an action plan. Counselling can be delivered in person or through validated remote pathways, but it should allow questions and access to appropriate clinical follow-up.

There is no single worldwide starting age. Recommendations differ by country, available resources and risk; many programmes consider regular mammography from age 40 or 50. In India, public population-based screening focuses on breast awareness and clinical assessment from age 30, while mammography is selected according to age, findings and risk. Discuss family history and previous breast disease with a clinician.

A Pap smear examines cervical cells for abnormal changes. An HPV test looks for high-risk human papillomavirus types that can cause those changes. HPV-based testing is increasingly preferred for primary screening, but the available programme determines the test and interval.

Use the ABCDE warning signs: asymmetry, irregular border, varied colour, increasing diameter and evolution or change. A new, changing, bleeding, itching or non-healing pigmented lesion should be examined; not every suspicious mole is cancer.

Not every cancer produces a measurable marker, and small or biologically different tumours may not raise the level. Tumour markers cannot by themselves rule cancer in or out; they are interpreted with examination, imaging and pathology.

Simple biopsy results may be available within several working days, but complex pathology, immunohistochemistry, molecular tests or outside review can take longer. Ask which result is pending and whether treatment decisions can safely wait for it.

Some tumours are rare or have overlapping microscopic appearances. Specialist review may refine the tumour type, grade or biomarker result and can alter surgery, drug selection or the need for further testing.

Yes. Infection, inflammation, healing tissue and some benign conditions can absorb the PET tracer. PET findings must be interpreted with the CT appearance, clinical context and, when necessary, biopsy.

Usually not. A blood-based liquid biopsy can identify some tumour-related genetic changes and is useful in selected situations, especially when tissue is insufficient or difficult to obtain. It may miss abnormalities, and tissue remains important for confirming the cancer type and architecture.

No. Some cancers occur despite healthy behaviour and cannot currently be prevented. However, avoiding established risks, vaccination and appropriate screening can reduce the chance of several cancers or detect them earlier.

Smoking and smokeless tobacco expose tissues to carcinogens and are linked to cancers of the lung, mouth, throat, oesophagus, pancreas, bladder and several other organs. Stopping helps at any age; behavioural support and cessation medicines improve the chance of success.

Cancer risk generally rises with the amount consumed, and no alcohol is the lowest-risk option. Alcohol is linked to cancers including breast, liver, mouth, throat, oesophagus and colorectum.

Excess body fat is associated with several cancers, including colorectal, postmenopausal breast, endometrial, kidney and oesophageal cancers. Sustainable eating patterns, regular activity, adequate sleep and medical support are preferable to extreme diets.

Regular moderate activity and strength work can lower the risk of several chronic diseases and some cancers. Start at a safe level and build gradually; people with major medical problems should obtain individual advice.

Important examples include HPV, hepatitis B and C, Helicobacter pylori, Epstein-Barr virus and HIV-associated immune suppression. Vaccination, safe practices, testing and treatment can reduce risk in appropriate people.

HPV vaccination prevents infections responsible for most cervical cancers and several other anogenital and head-and-neck cancers. Hepatitis B vaccination reduces the risk of chronic hepatitis B and liver cancer. Vaccination schedules depend on age, immune status and national policy.

Reducing intense ultraviolet exposure helps lower risk. Use shade, protective clothing and broad-spectrum sunscreen, avoid deliberate tanning and examine changing or non-healing lesions.